彭娟　崔慢慢

[摘要] 目的 探討樹突細(xì)胞-細(xì)胞因子誘導(dǎo)的殺傷細(xì)胞（DC-CIK）免疫治療聯(lián)合化療治療晚期卵巢癌的效果及對免疫功能的影響。 方法 按照隨機(jī)數(shù)字表法將2015年1月～2017年12月成都市新都區(qū)人民醫(yī)院收治的70例晚期卵巢癌患者分為兩組，對照組（n = 35）接受紫杉醇聯(lián)合順鉑化療，觀察組（n = 35）在對照組治療方案基礎(chǔ)上聯(lián)合DC-CIK免疫治療。治療3個(gè)療程，隨訪6個(gè)月后比較兩組患者臨床治療效果，并比較治療前后兩組患者免疫功能指標(biāo)（CD3+、CD4+、CD8+、CD19、CD16+CD56+），記錄并比較兩組患者治療過程中的不良反應(yīng)。 結(jié)果 隨訪6個(gè)月后，觀察組疾病控制率、客觀緩解率均高于對照組，差異有統(tǒng)計(jì)學(xué)意義（P < 0.05）。觀察組肝功能損害、骨髓抑制發(fā)生率均低于對照組，且觀察組總不良反應(yīng)總發(fā)生率低于對照組，差異有統(tǒng)計(jì)學(xué)意義（P < 0.05）。兩組患者治療后CD3+、CD4+、CD19、CD16+CD56+高于治療前，CD8+低于治療前，且觀察組治療后CD3+、CD4+、CD19、CD16+CD56+高于對照組，CD8+低于對照組，差異有統(tǒng)計(jì)學(xué)意義（P < 0.05）。 結(jié)論 DC-CIK細(xì)胞免疫治療聯(lián)合化療能顯著提高臨床治療效果，增強(qiáng)患者免疫功能，且不良反應(yīng)少，值得臨床推廣。

[關(guān)鍵詞] DC-CIK細(xì)胞免疫治療;化療;晚期卵巢癌;臨床療效;免疫功能

[中圖分類號] R737.31? ? ? ? ? [文獻(xiàn)標(biāo)識碼] A? ? ? ? ? [文章編號] 1673-7210（2019）06（b）-0059-04

Effect of DC-CIK cellular immunotherapy combined with chemotherapy on clinical efficacy and immune function in patients with advanced ovarian cancer

PENG Juan1? ?CUI Manman2

1.Department of Obstetrics and Gynecology， Xindu District People′s Hospital of Chengdu， Sichuan Province， Chengdu? ?610501， China; 2.Department of Gynaecology， Sichuan Provincial People′s Hospital， Sichuan Province， Chengdu? ?610072， China

[Abstract] Objective To explore the effect of dendritic cell-cytokine induced killer cell （DC-CIK） immunotherapy combined with chemotherapy for patients with advanced ovarian cancer and its influence on immune function. Methods A total of 70 patients with advanced ovarian cancer in Xindu District People′s Hospital of Chengdu from January 2015 to December 2017 was divided into two groups according to the random number table method. The control group （n = 35） was treated with Paclitaxel combined with Cisplatin， and the observation group （n = 35） was treated with DC-CIK immunotherapy on the base of control group. Continuous treatment for three courses， and follow up for 6 months， the clinical efficacy between two groups was compared. The comparisons of immune function indexes such as CD3+， CD4+， CD8+， CD19， CD16+CD56+ between two groups before and after treatment was conducted. The adverse reactions during the course of treatment were recorded and compared between the two groups. Results Six months after followed up， the disease control rate and objective remission rate in the observation group were higher than those in the control group， the differences were statistically significant （P < 0.05）. The liver dysfunction and bone marrow suppression in the observation group were respectively lower than those in the control group， and the total incidence of adverse reactions in the observation group was lower than that in the control group， the differences were statistically significant （P < 0.05）. After treatment， the levels of CD3+， CD4+， CD19 and CD16+CD56+ in two groups were significantly higher than those before treatment， and CD8+ level was lower than that before treatment， and the levels of CD3+， CD4+， CD19 and CD16+CD56+ in the observation group were higher than those in the control group， while the CD8+ level in the observation group was lower than that in the control group， the differences were statistically significant （P < 0.05）. Conclusion DC-CIK cell immunotherapy combined with chemotherapy can significantly improve the clinical efficacy and enhance immune function， which has fewer adverse reactions and worthy of clinical promotion.